Literature DB >> 22569085

Why do some depressed outpatients who are in remission according to the Hamilton Depression Rating Scale not consider themselves to be in remission?

Mark Zimmerman1, Jennifer A Martinez, Naureen Attiullah, Michael Friedman, Cristina Toba, Daniela A Boerescu, Moataz Rahgeb.   

Abstract

OBJECTIVE: In treatment studies of depression, remission is typically defined narrowly, based on scores on symptom severity scales. Patients treated in clinical practice, however, define the concept of remission more broadly and consider functional status, coping ability, and life satisfaction as important indicators of remission status. In the present report from the Rhode Island Methods to Improve Diagnostic Assessment and Services project, we examined how many depressed patients in ongoing treatment who scored in the remission range on the 17-item Hamilton Depression Rating scale (HDRS) did not consider themselves to be in remission from their depression. Among the HDRS remitters, we compared the demographic and clinical characteristics of patients who did and did not consider themselves to be in remission.
METHOD: From March 2009 to July 2010, we interviewed 274 psychiatric outpatients diagnosed with DSM-IV major depressive disorder who were in ongoing treatment. The patients completed measures of depressive and anxious symptoms, psychosocial functioning, and quality of life.
RESULTS: Approximately one-half of the patients scoring 7 and below on the HDRS (77 of 140 patients for whom self-reported remission status was available) did not consider themselves to be in remission. The self-described remitters had significantly lower levels of depression and anxiety than the patients who did not consider themselves to be in remission (P < .001). Compared to patients who did not consider themselves to be in remission, the remitters reported significantly better quality of life (P < .001) and less functional impairment due to depression (P < .001). Remitters were significantly less likely to report dissatisfaction in their mental health (P < .01), had higher positive mental health scores (P < .001), and reported better coping ability (P < .001).
CONCLUSIONS: Some patients who meet symptom-based definitions of remission nonetheless experience low levels of symptoms or functional impairment or deficits in coping ability, thereby warranting a modification in treatment. The findings raise caution in relying exclusively on symptom-based definitions of remission to guide treatment decision-making in clinical practice. © Copyright 2012 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22569085     DOI: 10.4088/JCP.11m07203

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  19 in total

1.  Cognitive Behavioral Analysis System of Psychotherapy as group psychotherapy for chronically depressed inpatients: a naturalistic multicenter feasibility trial.

Authors:  Lena Sabaß; Frank Padberg; Claus Normann; Vera Engel; Carsten Konrad; Kristina Helmle; Andrea Jobst; Andrew Worlitz; Eva-Lotta Brakemeier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-09-27       Impact factor: 5.270

Review 2.  Important clinical features of atypical antipsychotics in acute bipolar depression that inform routine clinical care: a review of pivotal studies with number needed to treat.

Authors:  Keming Gao; Chengmei Yuan; Renrong Wu; Jun Chen; Zuowei Wang; Yiru Fang; Joseph R Calabrese
Journal:  Neurosci Bull       Date:  2015-05-30       Impact factor: 5.203

3.  Predictors of remission from generalized anxiety disorder and major depressive disorder.

Authors:  Kristen M Kelly; Briana Mezuk
Journal:  J Affect Disord       Date:  2016-10-26       Impact factor: 4.839

Review 4.  Comparing the effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in the treatment of depression: a systematic review and meta-analysis.

Authors:  Beppe Micallef-Trigona
Journal:  Depress Res Treat       Date:  2014-07-21

5.  A study of remitted and treatment-resistant depression using MMPI and including pessimism and optimism scales.

Authors:  Masatoshi Suzuki; Michio Takahashi; Katsumasa Muneoka; Koichi Sato; Kenji Hashimoto; Yukihiko Shirayama
Journal:  PLoS One       Date:  2014-10-03       Impact factor: 3.240

6.  Broader conceptualization of remission assessed by the remission from depression questionnaire and its association with symptomatic remission: a prospective, multicenter, observational study.

Authors:  Alonso Montoya; Jeremie Lebrec; Karen Mary Keane; Irene Fregenal; Antonio Ciudad; Ángel Moríñigo; Luis Agüera-Ortiz; Irene Romera; Inmaculada Gilaberte; Mark Zimmerman
Journal:  BMC Psychiatry       Date:  2016-10-19       Impact factor: 3.630

7.  Daily activity level improvement with antidepressant medications predicts long-term clinical outcomes in outpatients with major depressive disorder.

Authors:  Manish K Jha; Raymond B Teer; Abu Minhajuddin; Tracy L Greer; A John Rush; Madhukar H Trivedi
Journal:  Neuropsychiatr Dis Treat       Date:  2017-03-15       Impact factor: 2.570

8.  Neuropsychological and socio-occupational functioning in young psychiatric outpatients: a longitudinal investigation.

Authors:  Rico S C Lee; Daniel F Hermens; M Antoinette Redoblado-Hodge; Sharon L Naismith; Melanie A Porter; Manreena Kaur; Django White; Elizabeth M Scott; Ian B Hickie
Journal:  PLoS One       Date:  2013-03-01       Impact factor: 3.240

9.  Evaluation of a spirituality informed e-mental health tool as an intervention for major depressive disorder in adolescents and young adults - a randomized controlled pilot trial.

Authors:  Badri Rickhi; Ania Kania-Richmond; Sabine Moritz; Jordan Cohen; Patricia Paccagnan; Charlotte Dennis; Mingfu Liu; Sonya Malhotra; Patricia Steele; John Toews
Journal:  BMC Complement Altern Med       Date:  2015-12-24       Impact factor: 3.659

Review 10.  Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient.

Authors:  Oloruntoba J Oluboka; Martin A Katzman; Jeffrey Habert; Diane McIntosh; Glenda M MacQueen; Roumen V Milev; Roger S McIntyre; Pierre Blier
Journal:  Int J Neuropsychopharmacol       Date:  2018-02-01       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.